Takafumi Koyama - Concepedia

Author

Takafumi Koyama

Also Known As

Koyama Takafumi, Koyama, Takafumi, N. Prasongsook, T Koyama, T. Koyama, Takafumi Koyama, Takafumi Koyoma, Takaki Koyama, Tsuguo Koyama, Yoo Kyum Kim

466

Publications

Citations

H-Index

Concepts

All Affiliations

Tokyo National Hospital National Cancer Center Hospital East National Cancer Centre Japan National Cancer Center Kyoto University

About

Takafumi Koyama is an author at Tokyo National Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	863
2	Cell Biology	4	4	134
3	Health Sciences	3	3	429
4	Engineering	2	2	46
5	Biomedical Engineering	1	1	16

Takafumi Koyama

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study Kuniko Sunami, Hitoshi Ichikawa, Takashi Kubo, Cancer Science Actionable Gene AberrationsCancer PathologyHospital‐based StudyGenetic EpidemiologyPathology	2019	351
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study Shubham Pant, Martin Schüler, Gopa Iyer, The Lancet Oncology Fgfr AlterationsMedicinePathologyAdvanced Solid TumoursFibroblast Growth Factor	2023	175
First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors Toshio Shimizu, Yutaka Fujiwara, Kan Yonemori, Clinical Cancer Research	2021	90
Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study Shunji Takahashi, Yutaka Fujiwara, Kenji Nakano, Cancer Science	2021	71
Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer Ikuko Nakamura, Shinji Kohsaka, Masachika Ikegami, npj Precision Oncology	2021	52
Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors Sylvie Rottey, Jeffrey Clarke, Kyaw Aung, EUR Research Repository (Erasmus University Rotterdam)	2022	50
Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort Toshihiko Doi, Yutaka Fujiwara, Takafumi Koyama, The Oncologist	2020	46
Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice Hanae Ida, Takafumi Koyama, Takaaki Mizuno, Cancer Science PathologyCgp TestsCancer RegistrationTumor BiologyMetastatic Solid Tumor	2022	46
Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors Toshio Shimizu, Takako Eguchi Nakajima, Noboru Yamamoto, Investigational New Drugs MedicineImmunologyAdvanced Solid TumorsImmune Checkpoint InhibitorAntibody Engineering	2022	45
Agonistic and antagonistic effects of zearalenone, an etrogenic mycotoxin, on SKN, HHUA, and HepG2 human cancer cell lines. G S Withanage, Hideo Murata, Takafumi Koyama, PubMed Chemoprevention StrategyToxic EffectsPathologyMycotoxinsCancer Biology	2001	41

Page 1